The Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025 would amend the Federal Food, Drug, and Cosmetic Act to create a pathway for reciprocal marketing approvals. A covered product that is lawfully marketed abroad could receive a reciprocal US approval if it meets specified eligibility criteria and the Secretary determines safety and effectiveness.
The bill also contemplates postmarket study requirements, labeling negotiations, and a congressional disapproval mechanism that can block the decision. The overarching goal is to accelerate access to medicines and devices while maintaining safeguards tied to US standards.
At a Glance
What It Does
The bill adds Section 524C to authorize reciprocal marketing approval for drugs, biologics, and devices that are legally marketed abroad. An approved foreign product can be treated as if it has a US approval or clearance for related US processes, subject to safety hurdles and postmarket obligations.
Who It Affects
Sponsors seeking reciprocal approval, FDA staff implementing the process, and consumers who could gain earlier access to therapies authorized abroad. The framework also implicates manufacturers obligated to provide English-language dossiers and labeling for US consideration.
Why It Matters
If adopted, the US could access lifesaving treatments more quickly by leveraging foreign approvals, potentially shortening time-to-market for urgent therapies while raising questions about harmonization, surveillance, and domestic safety commitments.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Reciprocity Act would create a formal pathway for US marketing approvals to be granted based on foreign authorization. Under Section 524C, a drug, biological product, or device that is already lawfully marketed in one or more foreign countries (including the UK) could qualify for reciprocal marketing approval in the United States.
Eligibility hinges on several criteria: the product must be authorized abroad, no safety or effectiveness concerns have led to a withdrawal or rescission of any US approval related to the product, and there must be a public health or unmet medical need in the United States. If these conditions are met, the Secretary may grant reciprocal marketing approval, treating the foreign-approval product as if it has an equivalent US approval or clearance status for the purposes of US marketing.
The bill places concrete steps around the process. The Secretary must receive a completed request and the accompanying country dossier translated into English for each eligible country.
The Secretary is required to issue a decision within 30 days of receiving the request, though the decision would take effect only subject to a Congressional disapproval pathway. During the 30-day window, negotiations on labeling and, for devices, classification under existing FDA mechanisms take place to ensure US requirements would be met.
If the Secretary declines reciprocal approval, the bill creates a formal reporting obligation to Congress and allows for postmarket studies to address safety or effectiveness concerns.The statute also contemplates that labeling, postapproval surveillance, and device classification considerations may influence whether a product would otherwise require more traditional US premarket pathways. It keeps the existing safety framework in place by allowing the Secretary to condition approval on postmarket commitments and to rely on the same safety data standards used for domestically approved products.
Finally, the bill requires outreach to encourage eligible sponsors to pursue reciprocal approval, and defines the scope of products eligible for consideration.
The Five Things You Need to Know
The Secretary may grant reciprocal marketing approval within 30 days of receiving a valid request, subject to safety and effectiveness review.
Eligibility requires that the product is lawfully marketed in at least one foreign country on the list (or in the United Kingdom).
The Secretary can require postmarket studies to address safety or effectiveness before or after granting reciprocal approval.
For labeling and devices, the sponsor must provide an English-language dossier and devices may be reclassified or otherwise validated under existing device pathways.
Congress can disapprove the FDA decision via a joint resolution, effectively blocking the reciprocal approval.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short Title and Purpose
This section provides the formal citation for the act as the Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025 and sets the overall objective of creating a reciprocal pathway for marketing approvals across drugs, biologics, and devices. It frames the balance between accelerating access and maintaining safety standards by tying the new authority to existing FDA and Public Health Service mechanisms.
Reciprocal Marketing Approval Program
Section 524C establishes the core mechanism. A covered product with reciprocal marketing approval abroad may be deemed eligible for US consideration as if it held an equivalent US approval or clearance. Eligibility requires foreign authorization, absence of safety or effectiveness concerns that would have led to withdrawal in the US, no current rescission of US authorization, and a medical need domestically. The Secretary may grant the reciprocal approval and may condition it on postmarket studies. The section also requires the sponsor to provide English translations of foreign dossiers and directs labeling negotiations during a 30-day window; for devices, it includes classification actions to determine whether a traditional US pathway (510(k) or PMA) would be required absent reciprocal approval. Finally, Congress can block the decision with a joint resolution, and the act sets up reporting and applicability rules consistent with FDA processes.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- US patients with imminent access to therapies approved abroad who previously faced delays awaiting US approval
- Sponsors of foreign-authorized products seeking faster entry into the US market
- Foreign manufacturers pursuing US access who will leverage the reciprocal pathway
- Healthcare providers and systems that can source therapies sooner for patients in need
- Payors and health plans that may benefit from earlier availability of innovative treatments
Who Bears the Cost
- FDA workload and potential need for new postmarket data obligations tied to reciprocal approvals
- US manufacturers facing direct competition or shifts in market timing due to expedited foreign-derived entries
- Hospitals and clinics may bear transitional costs related to updated labeling, pharmacovigilance, and stewardship requirements
- Payors may encounter uncertainty around pricing and coverage given faster access to foreign-approved therapies
- Small sponsors may incur translation, documentation, and regulatory preparation costs to pursue reciprocal status
Key Issues
The Core Tension
Speed to market via reciprocal foreign approvals versus the assurance of US-equivalent safety data. The bill seeks to harmonize international approvals with domestic safety expectations, but differences in regulatory rigor, postmarket surveillance, and labeling practices could create gaps that the US must vigilantly address.
The bill embraces faster access by leaning on foreign regulatory decisions, but it does not remove the US safety gate. Instead, it allows the Secretary to require postmarket studies to mitigate residual risk.
A major tension is whether foreign approvals consistently meet US standards for specific safety and effectiveness data, especially for devices whose clearance processes can diverge from US norms. The requirement to provide English translations and to negotiate labeling within a 30-day window introduces operational risks, including potential delays if dossiers are incomplete or labeling conflicts arise.
The Congressional disapproval mechanism adds a political check to the otherwise administrative process, but it could also create a veto dynamic that complicates timely access in emergency contexts. Finally, the applicability clause ties reciprocal approval to the same statutory framework that governs traditional FDA approvals, ensuring consistency but highlighting the dependence on the quality and comparability of foreign regulatory reviews.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.